Pharmaniaga’s long-term outlook positive


CGS-CIMB Research in a report said it projects decent earnings growth for the Pharmaniaga in 2023 and 2024.

KUALA LUMPUR: The long-term outlook for pharmaceutical firm Pharmaniaga Bhd is expected to remain positive, despite weak filled-and-finished vaccine sales during the first quarter of its current financial year.

CGS-CIMB Research in a report said it projects decent earnings growth for the group in 2023 and 2024.

The research house also expects long-term earnings contribution from the company’s entry into the manufacturing of biopharmaceuticals.

“We see manufacturing and its logistics and distribution division revenues tapering towards the end of 2022.

“However, Pharmaniaga’s longer term prospects are supported by a 10-year extension of its concession agreement (to be finalised in the third quarter of this year); its plans to set up a halal vaccine manufacturing facility by end-2024; and a fill-and-finish facility for recombinant human insulin products by 2025.”Pharmaniaga posted a net profit of RM27.73mil in the first quarter ended March 31, 2022, a 19.8% increase over RM23.14mil in the previous corresponding quarter.

The pharmaceuticals group reported revenue of RM962.17mil, a 21.26% improvement over the comparative quarter.

“This improved performance was attributable to healthy growth across the group’s concession and Indonesian businesses as a result of strong demand from customers, subsequent to the resumption of normal business activities as usual after the Covid-19 pandemic,” it said in a Bursa Malaysia filing.

CGS-CIMB Reserach noted that Pharmaniaga’s first quarter core net profit climbed 21.1% year-on-year to RM30mil on better manufacturing, logistics and distribution businesses and Indonesia earnings.

“Quarter-on-quarter, it plunged 70.2% on weaker manufacturing and logistics and distribution profits.

“While first quarter core earnings per share formed 30% and 32% of our’s and Bloomberg’s 2022 consensus’ estimates respectively, we deem this as low, due to lower-than-expected contribution from the supply of filled-and-finished Sinovac Covid-19 vaccines.”

In its filing with Bursa Malaysia, Pharmaniaga said it is in the midst of finalising the logistics and distribution contract extension agreement with the Health Ministry.

“With regards to the Indonesian business, the division successfully staged a swift turnaround, highlighting the effectiveness of the reorganisation of the business to enhance its operational efficiency through an ongoing stock optimisation exercise and aggressive payment collection.”

Going forward, Pharmaniaga said it is strengthening its business footprint in Indonesia, which the company believes has huge untapped potential.

“The group will revamp the current business model of its logistics and distribution arm, PT Millennium Pharmacon International Tbk and increase the products portfolio of its manufacturing arm, PT Errita Pharma.

“With strategic business and marketing plans in place, the group is focusing to double up the revenue for the Indonesian division,” it said.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

Pharmaniaga , profit , CGS-CIMB ,

   

Next In Business News

PDB signs 6 additional agreements to sell working inventory and deadstock for RM132.93mil
AMMB secures MoF approval for sale of AmGeneral Insurance to Liberty Insurance
I-Bhd strides ahead with confidence following rebound in business
Kim Loong’s net profit jumps 38% to RM39.2mil in 1Q
Mah Sing to buy Tebrau land to develop RM469mil GDV project
KLCI jumps 16.62 points to 1-week high
OPEC boosts oil income in 2021, well completions drop
Garuda Indonesia halves debt with restructuring, on track for profit
Oil extends gains as major producers flag capacity limits
Stocks swing higher as China eases quarantine rules

Others Also Read